Turing Pharmaceuticals Fails to Keep Its Pledge to Cut Cost Of Daraprim
Turing Pharmaceuticals Fails to Keep Its Pledge to Cut Cost Of Daraprim

Turing Pharmaceuticals, a fully integrated biopharmaceutical company that focuses majorly on patients with unmet medical needs refuses to cut down the price of its lifesaving drug Daraprim.

It has come into notice that the company is reducing the price for hospitals by up to 50 percent for Daraprim, a drug that treats toxoplasmosis, a rare parasitic infection that mainly strikes pregnant women and HIV patients.

CEO Martin Shkreli on Tuesday announced that the company officials decided that kit was more important to cut the cost of the medicine to hospitals, according to The New York Times.

Daraprim is actually a 62-year-old pill and its patent has expired decades ago. Carlos del Rio, chairman of the HIV Medicine Association said changes made by Turing are just ‘window dressing’.

Imprimis Pharmaceuticals sells a custom-made version of the drug for 99 cents per capsule. Those sales were not a factor in Turing’s pricing strategy, chief marketing officer Nancy Retzlaff said Wednesday.

Nancy Retzlaff, Turing’s chief commercial officer, said, “A drug’s list price is not the primary factor in determining patient affordability and access. A reduction in Daraprim’s list price would not translate into a benefit to patients”.

Del Rio said at the beginning most of the patients are treated at hospitals but they are very soon taken home and rest of the treatment is carried out at home. Therefore, the lowering of prices for hospitals is not going to work.

Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate